<DOC>
	<DOCNO>NCT00102895</DOCNO>
	<brief_summary>The main purpose research study see study drug , name CP-724,714 , help treatment certain breast cancer spread location body . Other goal study measure long may take cancer get bad ( progress ) , see side effect study drug , check amount study drug blood different time , check see relationship certain blood test patient may respond study drug . About 25 subject 4 site ( hospital clinic ) Bulgaria Russia involve trial . Participation study last 48 week , depend participant 's toleration study drug response tumor ( ) study drug . All participant receive CP-724,714 , daily dose 250 mg ( 4 pill ) every 12 hour .</brief_summary>
	<brief_title>A Research Study CP-724,714 Patients With HER2 Overexpressing Metastatic Breast Cancer</brief_title>
	<detailed_description>Pfizer decide terminate clinical protocol A4031003 October 7 , 2005 due excessive number patient grade 3 liver function test elevation lack efficacy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Signed write voluntary informed consent Histologically cytologically confirm breast cancer Stage IV ( metastatic ) breast cancer Biopsy ( fresh archival ) primary breast cancer metastatic site demonstrate HER2 gene amplification determine studyspecified central laboratory fluorescence situ hybridization ( FISH ) Prior treatment progressive disease least 1 2 cytotoxic chemotherapy regimen ( ) metastatic disease Those use investigational HER2 inhibitor appropriate access approve HER2 inhibitor ( e.g. , Herceptin® ) treatment currently available HER2 inhibitor inappropriate Limited visceral disease burden ( i.e. , &lt; 30 % involvement organ ) limit diseaserelated symptom ( i.e. , well control supportive care measure ) Presence least one measurable target lesion [ i.e. , malignant tumor mass accurately measure least 1 dimension &gt; =2 cm conventional radiographic technique magnetic resonance imaging , &gt; =1 cm spiral CT scan per RECIST ] , exclude previously irradiate lesion , bone metastasis pleural effusion sole manifestation disease . If measurable disease restrict solitary lesion , neoplastic nature must confirm cytology/histology Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient available treatment , monitoring , followup . Willing able comply schedule visit , therapy plan , laboratory test blood sample pharmacokinetic ( PK ) analyse Recovery baseline NCI CTCAE Version 3.0 Grade 1 toxicity acute effect related prior treatment , except alopecia Adequate Bone Marrow Function , include : . Absolute neutrophil count ( ANC ) &gt; =1500 cells/mm3 ; b. Platelets &gt; =100,000 cells/mm3 Adequate Renal Function , include : . Estimated creatinine clearance &gt; =60 mL/min ; b. SrCr &lt; 1.5 x ULN Adequate Liver Function , include : a. Bilirubin &lt; =ULN ( upper limit normal ) ; b. AST ( SGOT ) &lt; =2.5 x ULN ; c. ALT ( SGPT ) &lt; =2.5 x ULN Adequate Cardiac Function , include : . 12Lead electrocardiogram ( ECG ) normal trace non clinically significant change require medical intervention ; b. QTc interval &lt; =450 msec without history Torsades de Pointes symptomatic QTc abnormality ; c. Left ventricular ejection fraction ( LVEF ) &gt; = institutional low limit normal 45 % measure echocardiogram multi gate radionuclide angiography ( MUGA ) within 4 week prior start study treatment &gt; = 18 year old Female Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 4 week study Women pregnant breastfeed Women positive pregnancy test enrollment within 72 hour prior study drug administration Prior treatment trastuzumab ( Herceptin® ) HER2targeting agent [ e.g. , lapatinib ( GW572016 ) , pertuzumab ( Omnitarg™ ; rhuMab 2C4 ) , CI 1033 , EKB 569 , CP 724,714 ] Cumulative dose &gt; 450 mg/m2 doxorubicin doxorubicin equivalent Prior highdose chemotherapy require hematopoetic stem cell transplantation within 12 month study treatment start Radiotherapy , investigational chemotherapy , biologic therapy within 4 week study treatment start Previous ( within last 5 year ) current malignancy arise site breast , except adequately treat basal cell squamous cell skin cancer situ carcinoma cervix uteri Known clinically suspect brain metastasis leptomeningeal disease ( screen CT scan require ) require therapy . Patients asymptomatic previously treat CNS metastasis longer require therapy corticosteroids/anticonvulsants least 4 week prior start study treatment eligible Any clinically significant gastrointestinal abnormality , may impair intake , transit absorption study drug , inability take oral medication tablet form , prior complete/partial gastrectomy intestinal resection , requirement H2 antagonists proton pump inhibitor Any mental disorder would limit understand render informed consent and/or compromise compliance requirement protocol Uncontrolled significant cardiovascular disease , include : a. Myocardial infarction within 12 month ; b. Uncontrolled angina within 6 month ; c. Congestive heart failure within 6 month leave ventricular ejection fraction local institutional low limit normal 45 % ; d. Diagnosed suspected congenital long QT syndrome ; e. Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , torsade de pointes ) ; f. Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) ; g. Any history second third degree heart block ( may eligible currently pacemaker ) ; h. Heart rate &lt; 50/minute preentry electrocardiogram ; i. Uncontrolled hypertension History druginduced hyperbilirubinemia Concurrent treatment approve investigational chemotherapy , hormonal therapy , immunotherapy , radiotherapy ( hormone replacement therapy permit ) Concurrent treatment H2 antagonists and/or proton pump inhibitor . However , H2 antagonists use treatment unexpected hypersensitivity reaction study period . Antacids allow 2 hour 2 hour study drug administration Concurrent treatment treatment within 4 week first dose potent and/or irreversible CYP3A4 inhibitor include : ketoconazole , itraconazole , troleandomycin , clarithromycin , erythromycin , ritonavir , indinavir , nelfinavir , saquinavir , nefazodone , mibefradil , amiodarone grapefruit juice Concurrent treatment treatment within 4 week first dose potent inducer CYP3A4 include : rifampin , rifabutin , rifamycins , phenytoin , barbiturate , carbamazepine , glucocorticoid , modafinil , phenobarbital , troglitazone , pioglitazone , efavirenz , nevirapine , dexamethasone , St. John 's wort Prisoners patient compulsorily detain involuntarily incarcerate ( e.g. , treatment infectious disease , psychiatric illness , etc . )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>